Clinical Performance of the Investigational GEM Hemochron® 100 in Populations Ages 18 Years and Older
Public ClinicalTrials.gov record NCT03074266. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to evaluate and verify the clinical accuracy of the Hemochron® MCS 7000 Whole Blood Microcoagulation System; a point-of-care, whole blood Activated Clotting Time (ACT) measurement in comparison with the Hemochron Signature Elite® Whole Blood Microcoagulation System; a 510(k) cleared predicate device. This is a multi-center, prospective method comparison, with data to be analyzed separately from each site as well as combined for all sites.
Study identification
- NCT ID
- NCT03074266
- Recruitment status
- Not listed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 140 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 8, 2017 (Actual)
- Primary completion
- Dec 2018 (Estimated)
- Completion
- Dec 2018 (Estimated)
- Last update posted
- Jul 26, 2018
2017 – 2018
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Accriva Study Site | Los Angeles | California | 90033 | — |
| Accriva Study Site | Sacramento | California | 95816 | — |
| Accriva Study Site | Aurora | Colorado | 80045 | — |
| Accriva Study Site | Baltimore | Maryland | 21215 | — |
| Accriva Study Site | Takoma Park | Maryland | 20912 | — |
| Accriva Study Site | New Brunswick | New Jersey | 08903 | — |
| Accriva Study Site | Chapel Hill | North Carolina | 27514 | — |
| Accriva Study Site | Falls Church | Virginia | 22042 | — |
| Accriva Study Site | Charleston | West Virginia | 25304 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03074266, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2018 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03074266 live on ClinicalTrials.gov.